Analyst confidence swells following positive FDA alignment on the company's pivotal gene therapy trial for Rett Syndrome.
Permanent J-Code from CMS aims to streamline reimbursement and broaden patient access for its graft-versus-host disease treatment.
Hardware manufacturer Canaan's landmark U.S. order and Cipher Mining's strategic AI partnerships fuel renewed investor confidence.
Genentech's Tecentriq combination therapy is the first maintenance treatment for extensive-stage small cell lung cancer, a significant advance in a hard-to-treat disease.
Fair Isaac's new direct-to-lender model threatens a core revenue stream for TransUnion and Equifax, sending shares sharply lower.
Broadcom leads the charge as tech giants like Microsoft and Meta pour billions into AI chips, boosting the entire sector.
A rally in a micro-cap explorer sparks sector-wide gains, with Lithium Americas jumping over 23% on speculative interest in domestic supply.
The AI leader's new valuation surpasses SpaceX, underscoring intense investor confidence and boosting key partners like Microsoft and Nvidia.